June 15, 2020 / 4:38 PM / a month ago

BRIEF-Sarepta Therapeutics Announces Positive Safety & Efficacy Data From SRP-9001 Micro-Dystrophin Gene Therapy Trial Published In JAMA Neurology

June 15 (Reuters) - Sarepta Therapeutics Inc:

* SAREPTA THERAPEUTICS ANNOUNCES POSITIVE SAFETY AND EFFICACY DATA FROM THE SRP-9001 MICRO-DYSTROPHIN GENE THERAPY TRIAL PUBLISHED IN JAMA NEUROLOGY

* SAREPTA THERAPEUTICS - SRP-9001 THERAPY WAS SAFE & TOLERABLE IN ALL PARTICIPANTS OVER 1-YEAR TIME PERIOD

* SAREPTA THERAPEUTICS - ALL ADVERSE EVENTS CONSIDERED MILD/MODERATE, THERE WERE NO SERIOUS ADVERSE EVENTS/EVIDENCE OF COMPLEMENT ACTIVATION IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below